While the regulatory filing omits specific share counts and pricing details, the company confirmed plans to trade on the Nasdaq Global Market under the ticker symbol APMD. The proceeds from the offering are earmarked for the ongoing FDA approval process, alongside broader research and development initiatives.

Oxnimbi remains the company’s sole clinical product. As the FDA review cycle continues, the transition to a public entity provides the necessary liquidity to move the drug from the laboratory into the commercial market, assuming the company receives the requisite regulatory clearance.